Evaluation of the Condition of Rheumatoid Arthritis After Treatment

Evaluation of the Condition After Xeljanz Treatment in Rheumatoid Arthritis Patients

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02157012

Enrollment

100

Registered

2014-06-05

Start date

2014-05-31

Completion date

2025-03-31

Last updated

2021-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Brief summary

To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients

Interventions

DRUGThe effectiveness of Xeljanz in rheumatoid arthritis patients

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Rheumatoid arthritis

Exclusion criteria

* Other connective tissue disease

Design outcomes

Primary

Measure	Time frame	Description
Change from baseline of clinical evaluation in rheumatoid arthritis	Every month	DAS28, SDAI, Blood testing, Plain radiograph, and Ultrasound will be performed.

Secondary

Measure	Time frame
Number of participants with adverse events	Every month

Countries

Japan

Contacts

Primary ContactYukio Nakamura, MD, PhD

yxn14@aol.jp

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026